263 related articles for article (PubMed ID: 22131882)
1. DNA-PK mediates AKT activation and apoptosis inhibition in clinically acquired platinum resistance.
Stronach EA; Chen M; Maginn EN; Agarwal R; Mills GB; Wasan H; Gabra H
Neoplasia; 2011 Nov; 13(11):1069-80. PubMed ID: 22131882
[TBL] [Abstract][Full Text] [Related]
2. Cell detachment modulates TRAIL resistance in ovarian cancer cells by downregulating the phosphatidylinositol 3-kinase/Akt pathway.
Lane D; Cartier A; Rancourt C; Piché A
Int J Gynecol Cancer; 2008; 18(4):670-6. PubMed ID: 17868340
[TBL] [Abstract][Full Text] [Related]
3. Cellular pharmacology of cis and trans pairs of platinum complexes in cisplatin-sensitive and -resistant human ovarian carcinoma cells.
O'Neill CF; Hunakova L; Kelland LR
Chem Biol Interact; 1999 Nov; 123(1):11-29. PubMed ID: 10597899
[TBL] [Abstract][Full Text] [Related]
4. CD133 and DNA-PK regulate MDR1 via the PI3K- or Akt-NF-κB pathway in multidrug-resistant glioblastoma cells in vitro.
Xi G; Hayes E; Lewis R; Ichi S; Mania-Farnell B; Shim K; Takao T; Allender E; Mayanil CS; Tomita T
Oncogene; 2016 Jan; 35(2):241-50. PubMed ID: 25823028
[TBL] [Abstract][Full Text] [Related]
5. TR3 modulates platinum resistance in ovarian cancer.
Wilson AJ; Liu AY; Roland J; Adebayo OB; Fletcher SA; Slaughter JC; Saskowski J; Crispens MA; Jones HW; James S; Fadare O; Khabele D
Cancer Res; 2013 Aug; 73(15):4758-69. PubMed ID: 23720056
[TBL] [Abstract][Full Text] [Related]
6. HDAC4-regulated STAT1 activation mediates platinum resistance in ovarian cancer.
Stronach EA; Alfraidi A; Rama N; Datler C; Studd JB; Agarwal R; Guney TG; Gourley C; Hennessy BT; Mills GB; Mai A; Brown R; Dina R; Gabra H
Cancer Res; 2011 Jul; 71(13):4412-22. PubMed ID: 21571862
[TBL] [Abstract][Full Text] [Related]
7. Curcumin-induced apoptosis in ovarian carcinoma cells is p53-independent and involves p38 mitogen-activated protein kinase activation and downregulation of Bcl-2 and survivin expression and Akt signaling.
Watson JL; Greenshields A; Hill R; Hilchie A; Lee PW; Giacomantonio CA; Hoskin DW
Mol Carcinog; 2010 Jan; 49(1):13-24. PubMed ID: 19676105
[TBL] [Abstract][Full Text] [Related]
8. EF24 induces G2/M arrest and apoptosis in cisplatin-resistant human ovarian cancer cells by increasing PTEN expression.
Selvendiran K; Tong L; Vishwanath S; Bratasz A; Trigg NJ; Kutala VK; Hideg K; Kuppusamy P
J Biol Chem; 2007 Sep; 282(39):28609-28618. PubMed ID: 17684018
[TBL] [Abstract][Full Text] [Related]
9. An integrated genomic-based approach to individualized treatment of patients with advanced-stage ovarian cancer.
Dressman HK; Berchuck A; Chan G; Zhai J; Bild A; Sayer R; Cragun J; Clarke J; Whitaker RS; Li L; Gray J; Marks J; Ginsburg GS; Potti A; West M; Nevins JR; Lancaster JM
J Clin Oncol; 2007 Feb; 25(5):517-25. PubMed ID: 17290060
[TBL] [Abstract][Full Text] [Related]
10. Downregulation of AKT reverses platinum resistance of human ovarian cancers in vitro.
Hahne JC; Honig A; Meyer SR; Gambaryan S; Walter U; Wischhusen J; Häussler SF; Segerer SE; Fujita N; Dietl J; Engel JB
Oncol Rep; 2012 Dec; 28(6):2023-8. PubMed ID: 22992944
[TBL] [Abstract][Full Text] [Related]
11. ATP11B mediates platinum resistance in ovarian cancer.
Moreno-Smith M; Halder JB; Meltzer PS; Gonda TA; Mangala LS; Rupaimoole R; Lu C; Nagaraja AS; Gharpure KM; Kang Y; Rodriguez-Aguayo C; Vivas-Mejia PE; Zand B; Schmandt R; Wang H; Langley RR; Jennings NB; Ivan C; Coffin JE; Armaiz GN; Bottsford-Miller J; Kim SB; Halleck MS; Hendrix MJ; Bornman W; Bar-Eli M; Lee JS; Siddik ZH; Lopez-Berestein G; Sood AK
J Clin Invest; 2013 May; 123(5):2119-30. PubMed ID: 23585472
[TBL] [Abstract][Full Text] [Related]
12. Dual mTORC1/2 Inhibition as a Novel Strategy for the Resensitization and Treatment of Platinum-Resistant Ovarian Cancer.
Musa F; Alard A; David-West G; Curtin JP; Blank SV; Schneider RJ
Mol Cancer Ther; 2016 Jul; 15(7):1557-67. PubMed ID: 27196780
[TBL] [Abstract][Full Text] [Related]
13. Checkpoint kinase 2 (Chk2) supports sensitivity to platinum-based treatment in high grade serous ovarian cancer.
Alkema NG; Tomar T; van der Zee AG; Everts M; Meersma GJ; Hollema H; de Jong S; van Vugt MA; Wisman GB
Gynecol Oncol; 2014 Jun; 133(3):591-8. PubMed ID: 24657486
[TBL] [Abstract][Full Text] [Related]
14. Akt promotes cisplatin resistance in human ovarian cancer cells through inhibition of p53 phosphorylation and nuclear function.
Fraser M; Bai T; Tsang BK
Int J Cancer; 2008 Feb; 122(3):534-46. PubMed ID: 17918180
[TBL] [Abstract][Full Text] [Related]
15. XIAP regulates Akt activity and caspase-3-dependent cleavage during cisplatin-induced apoptosis in human ovarian epithelial cancer cells.
Asselin E; Mills GB; Tsang BK
Cancer Res; 2001 Mar; 61(5):1862-8. PubMed ID: 11280739
[TBL] [Abstract][Full Text] [Related]
16. Plasminogen activator inhibitor 1 protects fibrosarcoma cells from etoposide-induced apoptosis through activation of the PI3K/Akt cell survival pathway.
Rømer MU; Larsen L; Offenberg H; Brünner N; Lademann UA
Neoplasia; 2008 Oct; 10(10):1083-91. PubMed ID: 18813358
[TBL] [Abstract][Full Text] [Related]
17. Akt confers cisplatin chemoresistance in human gynecological carcinoma cells by modulating PPM1D stability.
Ali AY; Kim JY; Pelletier JF; Vanderhyden BC; Bachvarov DR; Tsang BK
Mol Carcinog; 2015 Nov; 54(11):1301-14. PubMed ID: 25154814
[TBL] [Abstract][Full Text] [Related]
18. Tanshinone IIA acts via p38 MAPK to induce apoptosis and the down-regulation of ERCC1 and lung-resistance protein in cisplatin-resistant ovarian cancer cells.
Jiao JW; Wen F
Oncol Rep; 2011 Mar; 25(3):781-8. PubMed ID: 21165580
[TBL] [Abstract][Full Text] [Related]
19. Drug-induced caspase 8 upregulation sensitises cisplatin-resistant ovarian carcinoma cells to rhTRAIL-induced apoptosis.
Duiker EW; Meijer A; van der Bilt AR; Meersma GJ; Kooi N; van der Zee AG; de Vries EG; de Jong S
Br J Cancer; 2011 Apr; 104(8):1278-87. PubMed ID: 21487429
[TBL] [Abstract][Full Text] [Related]
20. The inhibition of Bid expression by Akt leads to resistance to TRAIL-induced apoptosis in ovarian cancer cells.
Goncharenko-Khaider N; Lane D; Matte I; Rancourt C; Piché A
Oncogene; 2010 Oct; 29(40):5523-36. PubMed ID: 20661217
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
